Resultado de búsqueda
17 de mar. de 2019 · We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K...
- R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
- 2019
19 de ene. de 2021 · An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
- Ziad Hijazi, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger...
- 2021
29 de mar. de 2020 · Among patients with atrial fibrillation with recent ACS or PCI in the AUGUSTUS trial, adding apixaban to a P2Y 12 inhibitor resulted in lower bleeding compared with VKA with a lower rate of death or rehospitalization.
18 de abr. de 2019 · Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an ...
- R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
- 2019
2 de jul. de 2019 · AUGUSTUS is the first trial with a two-by-two factorial design in patients with atrial fibrillation (AF) on combined antithrombotic therapy after an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), respectively. 1 Thereby, it allows the independent evaluation of the effects of prescribing apixaban ...
- Thomas Gremmel, Patrick Sulzgruber, Alexander Niessner
- 2019
26 de sept. de 2019 · An open-label, 2×2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
17 de mar. de 2019 · AUGUSTUS is an international, multicenter, open-label, randomized controlled trial with a two-by-two factorial design to compare Eliquis (apixaban) with vitamin K antagonists (VKAs) and aspirin with placebo in 4,614 patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing ...